These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36702180)

  • 1. Baricitinib for the treatment of intestinal Behçet's disease: A pilot study.
    Liu J; Yu X; Wang Z; Liu W; Liu X; Wang X; Zhang M; Zhao Y; Zhang F; Yang H; Zheng W
    Clin Immunol; 2023 Feb; 247():109241. PubMed ID: 36702180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib for the treatment of refractory vascular Behçet's disease.
    Wang Z; Wang X; Liu W; Wang Y; Liu J; Zhang L; Zhang S; Tian X; Zhao Y; Zheng W
    Clin Immunol; 2023 May; 250():109298. PubMed ID: 36967024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.
    Miyagawa I; Nakano K; Iwata S; Nakayamada S; Saito K; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Tanaka Y
    Arthritis Res Ther; 2019 Jun; 21(1):151. PubMed ID: 31228955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of infliximab refractory intestinal Behçet's syndrome: A retrospective cohort study from the Shanghai Behçet's syndrome database.
    Bao HF; Hou CC; Ye B; Zou J; Luo D; Cai JF; Shen Y; Guan JL
    Mod Rheumatol; 2023 Jan; 33(1):207-216. PubMed ID: 34932796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
    Tanida S; Inoue N; Kobayashi K; Naganuma M; Hirai F; Iizuka B; Watanabe K; Mitsuyama K; Inoue T; Ishigatsubo Y; Suzuki Y; Nagahori M; Motoya S; Nakamura S; Arora V; Robinson AM; Thakkar RB; Hibi T
    Clin Gastroenterol Hepatol; 2015 May; 13(5):940-8.e3. PubMed ID: 25245624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Behçet's disease.
    Kinoshita H; Nishioka H; Ikeda A; Ikoma K; Sameshima Y; Ohi H; Tatsuno M; Kouyama J; Kawamoto C; Mitsui T; Tamura Y; Hashimoto Y; Nishio M; Ogashiwa T; Saigusa Y; Maeda S; Kimura H; Kunisaki R; Koike K
    J Gastroenterol Hepatol; 2019 Nov; 34(11):1929-1939. PubMed ID: 31017728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease.
    Lee HJ; Kim YN; Jang HW; Jeon HH; Jung ES; Park SJ; Hong SP; Kim TI; Kim WH; Nam CM; Cheon JH
    World J Gastroenterol; 2012 Oct; 18(40):5771-8. PubMed ID: 23155319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.
    Yu J; Shin SJ; Park YJ; Kim HW; Lee BI; Ye BD; Kim GT; Kim SK; Kim JS; Kim YH; Jeong S; Cheon JH
    BMC Gastroenterol; 2023 Dec; 23(1):449. PubMed ID: 38114956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet's disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study.
    Lee SB; Hong HS; Lee CK; Lee BI; Kim S; Koh SJ; Yu H; Park JB; Hwang SW; Ye BD; Yang SK; Park SH;
    Korean J Intern Med; 2023 Sep; 38(5):661-671. PubMed ID: 37491721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J; Ji DN; Cai JF; Guan JL; Bao ZJ
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).
    Cheon JH; Kim HS; Han DS; Kim SK; Shin SJ; Kim JS; Ye BD; Song GA; Lee Y; Kim Y; Lee Y; Kim WH;
    Gut Liver; 2023 Sep; 17(5):777-785. PubMed ID: 36578194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease.
    Naganuma M; Sakuraba A; Hisamatsu T; Ochiai H; Hasegawa H; Ogata H; Iwao Y; Hibi T
    Inflamm Bowel Dis; 2008 Sep; 14(9):1259-64. PubMed ID: 18393375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
    Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
    Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease.
    Jung YS; Kim SW; Yoon JY; Lee JH; Jeon SM; Hong SP; Kim TI; Kim WH; Cheon JH
    Inflamm Bowel Dis; 2011 Oct; 17(10):2130-7. PubMed ID: 21910175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis.
    Chung SH; Park SJ; Hong SP; Cheon JH; Kim TI; Kim WH
    World J Gastroenterol; 2013 Aug; 19(32):5389-92. PubMed ID: 23983446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of capsule endoscopy for detecting small bowel lesions in patients with intestinal Behçet's disease.
    Arimoto J; Endo H; Kato T; Umezawa S; Fuyuki A; Uchiyama S; Higurashi T; Ohkubo H; Nonaka T; Takeno M; Ishigatsubo Y; Sakai E; Matsuhashi N; Nakajima A
    Dig Endosc; 2016 Mar; 28(2):179-85. PubMed ID: 26459917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.
    Miyazaki H; Watanabe D; Okamoto N; Tokunaga E; Ku Y; Takenaka H; Hoshi N; Ooi M; Kodama Y
    BMC Gastroenterol; 2022 Mar; 22(1):149. PubMed ID: 35346067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of patients with intestinal Behçet's disease requiring treatment with immunosuppressants or anti-TNFα antibody.
    Kimura Y; Asako K; Kikuchi H; Kono H
    Mod Rheumatol; 2016; 26(1):132-7. PubMed ID: 26025434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication.
    Kinoshita H; Kunisaki R; Yamamoto H; Matsuda R; Sasaki T; Kimura H; Tanaka K; Naganuma M; Maeda S
    Intern Med; 2013; 52(17):1855-62. PubMed ID: 23994973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.